Lp-PLA2 Activity
Test Mnemonic
PLAA2
CPT Codes
- 83698 - QTY (1)
Aliases
- Lipoprotein-associated Phospholipase A2
- Lp-PLA2 Activity Assay
Performing Laboratory
Cleveland HeartLab, Inc.
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Speckled or Tiger Top) | Refrigerated | Fasting is preferred, but not required. Gently invert tube 5 times immediately after draw. DO NOT SHAKE. Allow blood to clot 30 minutes. Centrifuge at 1300 rcf for 10 minutes. |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated | Fasting is preferred, but not required. Gently invert tube 5 times immediately after draw. DO NOT SHAKE. Allow blood to clot 30 minutes. Centrifuge at 1300 rcf for 10 minutes. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Refrigerated | 28 days |
| Ambient | 7 days |
| Frozen | 28 days |
Days Performed
Mon - Sat
Turnaround Time
4 - 5 days
Methodology
| Name | Description |
|---|---|
| Enzymatic |
Reference Range
| Lp PLA2 Activity | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Years | 99 Years | Normal | Goal (optimum): < or = 123 | nmol/min/mL | Years | 99 Years | Normal | High Risk: > 123 | nmol/min/mL |
Special Info
Fasting is preferred, but not required. Grossly hemolyzed specimens will be rejected.
Clinical Info
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low-density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, LpPLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies.